<?xml version="1.0" encoding="UTF-8"?>
<urlset xmlns="http://www.sitemaps.org/schemas/sitemap/0.9" 
        xmlns:image="http://www.google.com/schemas/sitemap-image/1.1">
  <url>
    <loc>https://openbell.ai/</loc>
    <lastmod>2026-11-20T22:10:32.818Z</lastmod>
    <changefreq>hourly</changefreq>
    <priority>1.0</priority>
  </url>
  <url>
    <loc>https://openbell.ai/support</loc>
    <lastmod>2026-11-20T22:10:32.818Z</lastmod>
    <changefreq>monthly</changefreq>
    <priority>0.7</priority>
  </url>
  <url>
    <loc>https://openbell.ai/privacy</loc>
    <lastmod>2026-11-20T22:10:32.818Z</lastmod>
    <changefreq>monthly</changefreq>
    <priority>0.5</priority>
  </url>
  <url>
    <loc>https://openbell.ai/terms</loc>
    <lastmod>2026-11-20T22:10:32.818Z</lastmod>
    <changefreq>monthly</changefreq>
    <priority>0.5</priority>
  </url>
  <url>
    <loc>https://openbell.ai/feed.json</loc>
    <lastmod>2026-11-20T22:10:32.818Z</lastmod>
    <changefreq>hourly</changefreq>
    <priority>0.8</priority>
  </url>
  <url>
    <loc>https://openbell.ai/news/LNG:1795210315000</loc>
    <lastmod>2026-11-20T21:31:55.000Z</lastmod>
    <changefreq>daily</changefreq>
    <priority>0.9</priority>
    <image:image>
      <image:loc>https://cdn.brandfetch.io/LNG/w/400/h/400?c=1idopYfmtR7ZKg8QMud</image:loc>
      <image:title>FERC Approves Cheniere Energy&#39;s Sabine Pass Expansion</image:title>
      <image:caption>FERC unanimously approved Cheniere Energy’s expansion of its Sabine Pass LNG terminal in Louisiana, allowing for three additional liquefaction trains that could add up to 950 billion cubic feet of annual production capacity. The first phase is projected to add more than 6 million tonnes per year of liquefaction capacity by the early 2030s. Cheniere called the approval a key step toward a final investment decision, but still needs additional permits and financing.</image:caption>
    </image:image>
  </url>
  <url>
    <loc>https://openbell.ai/news/GPN:1795201399000</loc>
    <lastmod>2026-11-20T19:03:19.000Z</lastmod>
    <changefreq>daily</changefreq>
    <priority>0.9</priority>
    <image:image>
      <image:loc>https://cdn.brandfetch.io/GPN/w/400/h/400?c=1idopYfmtR7ZKg8QMud</image:loc>
      <image:title>Global Payments&#39; Largest Shareholder GTCR Weighs Takeover</image:title>
      <image:caption>Global Payments’ largest shareholder, private-equity firm GTCR, is exploring a potential takeover of the payment technology company at an estimated value of about $50 billion. The discussions remain preliminary, and reports say other firms previously considered acquiring Global Payments but later dropped their interest.</image:caption>
    </image:image>
  </url>
  <url>
    <loc>https://openbell.ai/news/RMBS:1795201355000</loc>
    <lastmod>2026-11-20T19:02:35.000Z</lastmod>
    <changefreq>daily</changefreq>
    <priority>0.9</priority>
    <image:image>
      <image:loc>https://cdn.brandfetch.io/RMBS/w/400/h/400?c=1idopYfmtR7ZKg8QMud</image:loc>
      <image:title>Rambus Issues Mixed Guidance with Lowered Expectations</image:title>
      <image:caption>Rambus issued updated financial guidance that lowered its performance expectations, signaling a mixed outlook. The report provides no specific revenue or profit figures, percentage changes, or stock-price impact, but notes that the revision contrasts with industry peers that have beaten earnings expectations and raised guidance.</image:caption>
    </image:image>
  </url>
  <url>
    <loc>https://openbell.ai/news/NVO:1795201299000</loc>
    <lastmod>2026-11-20T19:01:39.000Z</lastmod>
    <changefreq>daily</changefreq>
    <priority>0.9</priority>
    <image:image>
      <image:loc>https://cdn.brandfetch.io/NVO/w/400/h/400?c=1idopYfmtR7ZKg8QMud</image:loc>
      <image:title>Novo Nordisk Receives FDA Approval for Sogroya® in Children with Turner Syndrome</image:title>
      <image:caption>The FDA approved Novo Nordisk’s once-weekly growth hormone Sogroya (somapacitan-beco) to treat growth failure in children aged 2.5 years and older with Turner syndrome. The company said it is the first and only once-weekly growth hormone option for this group, potentially reducing injection frequency compared with daily therapies. Sogroya is now approved for five growth-related disorders; the article reported no financial figures or stock-price impact.</image:caption>
    </image:image>
  </url>
  <url>
    <loc>https://openbell.ai/news/TTWO:1795201290000</loc>
    <lastmod>2026-11-20T19:01:30.000Z</lastmod>
    <changefreq>daily</changefreq>
    <priority>0.9</priority>
    <image:image>
      <image:loc>https://cdn.brandfetch.io/TTWO/w/400/h/400?c=1idopYfmtR7ZKg8QMud</image:loc>
      <image:title>Take-Two Interactive&#39;s Grand Theft Auto VI Generates $2.36 Billion in First-Day Sales</image:title>
      <image:caption>Grand Theft Auto VI generated an estimated $2.36 billion in launch-day revenue, with about 24.6 million units sold, according to Sensor Tower. The release is the first new entry in the franchise in 13 years. The Grand Theft Auto series has sold more than 470 million units worldwide, including over 230 million copies of Grand Theft Auto V.</image:caption>
    </image:image>
  </url>
  <url>
    <loc>https://openbell.ai/news/NVO:1795197695000</loc>
    <lastmod>2026-11-20T18:01:35.000Z</lastmod>
    <changefreq>daily</changefreq>
    <priority>0.9</priority>
    <image:image>
      <image:loc>https://cdn.brandfetch.io/NVO/w/400/h/400?c=1idopYfmtR7ZKg8QMud</image:loc>
      <image:title>FDA Approves Novo Nordisk&#39;s Sogroya® for Turner Syndrome in Children</image:title>
      <image:caption>The FDA approved Novo Nordisk’s once-weekly growth hormone Sogroya (somapacitan-beco) for children aged 2.5 years and older with growth failure associated with Turner Syndrome. The decision was supported by efficacy and safety results from the pivotal REAL8 trial. Sogroya is now indicated for growth hormone deficiency and four other growth-related conditions, including Idiopathic Short Stature, Noonan Syndrome, and short stature in children born Small for Gestational Age.</image:caption>
    </image:image>
  </url>
  <url>
    <loc>https://openbell.ai/news/ELCO:1795195966000</loc>
    <lastmod>2026-11-20T17:32:46.000Z</lastmod>
    <changefreq>daily</changefreq>
    <priority>0.9</priority>
    <image:image>
      <image:loc>https://cdn.brandfetch.io/ELCO/w/400/h/400?c=1idopYfmtR7ZKg8QMud</image:loc>
      <image:title>High Court Sanctions Eleco plc Takeover by Avocet Bidco</image:title>
      <image:caption>The High Court sanctioned Avocet Bidco Limited’s recommended all-cash acquisition of Eleco plc; Avocet is managed by Accel-KKR. Eleco shares are scheduled to trade for the final time on 27 November 2026, with AIM trading suspended on 30 November and admission cancelled on 1 December; shareholder payments are expected by 14 December. The transaction also triggered the exercise of 2.44 million employee and executive share options, including options held by CEO Jonathan Hunter and CFO Neil Pritchard.</image:caption>
    </image:image>
  </url>
</urlset>